Australia markets closed
  • ALL ORDS

    7,111.40
    +32.50 (+0.46%)
     
  • ASX 200

    6,824.70
    +24.30 (+0.36%)
     
  • AUD/USD

    0.7693
    -0.0019 (-0.25%)
     
  • OIL

    53.08
    +0.31 (+0.59%)
     
  • GOLD

    1,851.70
    -3.50 (-0.19%)
     
  • BTC-AUD

    41,007.77
    -948.62 (-2.26%)
     
  • CMC Crypto 200

    637.40
    -9.92 (-1.53%)
     
  • AUD/EUR

    0.6344
    -0.0005 (-0.08%)
     
  • AUD/NZD

    1.0693
    -0.0019 (-0.18%)
     
  • NZX 50

    13,323.46
    -75.64 (-0.56%)
     
  • NASDAQ

    13,483.29
    +116.89 (+0.87%)
     
  • FTSE

    6,687.72
    +48.87 (+0.74%)
     
  • Dow Jones

    30,960.00
    -36.98 (-0.12%)
     
  • DAX

    13,835.80
    +191.85 (+1.41%)
     
  • Hang Seng

    29,391.26
    -767.75 (-2.55%)
     
  • NIKKEI 225

    28,546.18
    -276.11 (-0.96%)
     

Pear Therapeutics to Participate in the 2020 RBC Capital Markets Healthcare Private Company Conference

·1-min read

Pear Therapeutics, Inc. today announced that Corey McCann, M.D., Ph.D., President and CEO, will participate in a fireside chat at the 2020 RBC Capital Markets Healthcare Private Company Conference on Wednesday, December 16 at 10:00 a.m. Eastern Time.

Pear Therapeutics is a privately held, prescription digital therapeutics company developing clinically validated, FDA-authorized software applications to treat serious disease.

About Pear Therapeutics
Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. Pear aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from FDA. Pear’s lead product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst™, for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201202005170/en/

Contacts

Media and Investors:
Meara Murphy
Director, Corporate Communications
meara.murphy@peartherapeutics.com